Heather A. Iocca
BioCryst Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Coagulation, Bradykinin, Polyphosphates, and Angioedema, Inflammasome and immune disorders, Immune Response and Inflammation, Hemophilia Treatment and Research, NF-κB Signaling Pathways
Most-Cited Works
- → NLRP3 Plays a Critical Role in the Development of Experimental Autoimmune Encephalomyelitis by Mediating Th1 and Th17 Responses(2010)419 cited
- → The Inflammasome Sensor, NLRP3, Regulates CNS Inflammation and Demyelination via Caspase-1 and Interleukin-18(2010)308 cited
- → Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial(2020)158 cited
- → Criteria for effective design, construction, and gene knockdown by shRNA vectors(2006)127 cited
- → Cutting Edge: ASC Mediates the Induction of Multiple Cytokines by Porphyromonas gingivalis via Caspase-1-Dependent and -Independent Pathways(2006)79 cited
- → Semaphorin 6D regulates the late phase of CD4 + T cell primary immune responses(2008)67 cited
- → Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)(2021)59 cited
- → Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study(2021)51 cited
- → Lymphotoxin β Receptor (LtβR): Dual Roles in Demyelination and Remyelination and Successful Therapeutic Intervention Using LtβR–Ig Protein(2007)49 cited
- → Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: A phase 3 randomized trial(2020)45 cited